Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75p -1.56% 47.25p 47.25p 47.50p 48.50p 47.25p 47.50p 678,289 16:28:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.3 15.2 4.7 10.2 222.59

Alliance Pharma (APH) Latest News

More Alliance Pharma News
Alliance Pharma Takeover Rumours

Alliance Pharma (APH) Share Charts

1 Year Alliance Pharma Chart

1 Year Alliance Pharma Chart

1 Month Alliance Pharma Chart

1 Month Alliance Pharma Chart

Intraday Alliance Pharma Chart

Intraday Alliance Pharma Chart

Alliance Pharma (APH) Discussions and Chat

Alliance Pharma Forums and Chat

Date Time Title Posts
30/9/201612:09Alliance Pharma pays Dividends738
15/7/201310:15ALLIANCE PHARMA – 2005 Strong Riser611
16/6/201111:57why the sell off1
13/2/200909:18Suddenly there's Life!14

Add a New Thread

Alliance Pharma (APH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:57:2147.7712,3095,880.49O
16:55:1147.6719,3949,245.59O
16:35:1947.2521,47110,145.05UT
16:29:1447.2521199.70AT
16:23:3347.251,817858.53AT
View all Alliance Pharma trades in real-time

Alliance Pharma (APH) Top Chat Posts

DateSubject
30/9/2016
09:20
Alliance Pharma Daily Update: Alliance Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 48p.
Alliance Pharma has a 4 week average price of 48.38p and a 12 week average price of 46.83p.
The 1 year high share price is 57.75p while the 1 year low share price is currently 40.50p.
There are currently 471,093,833 shares in issue and the average daily traded volume is 663,010 shares. The market capitalisation of Alliance Pharma is £222,591,836.09.
23/9/2016
12:08
pollnagorm: Share price interests me not his finances , not to be rude about it .
26/11/2015
08:19
pimpernel4: Fair enough and good luck to you ramridge. There seems to have been plenty of appetite at 44p this morning at just a 10% premium to the placement price. The compelling thing about APH is its relatively small free float of shares. As we saw earlier in the year it does not take much to get it motoring and the majority of the new shares must surely now sit in hands that are in it for the mid to long term. Let's see what the end of year share price is.
08/10/2015
15:09
domple: there must be a big seller as there have been tens and tens of £thousands bought recently and the share price hasn't moved much.
17/8/2015
09:17
rivaldo: RNS - interims confirmed for 9th September (a day earlier than last year!). Michael, thanks for post 611 above. I suspect your last paragraph is indeed the case as regards the rise in the share price, i.e simply that sellers have completed their disposals and prospects have brightened - plus the possibility of further (and larger) acquisitions.
12/8/2015
21:44
cisk: Michael, many thanks for the excellent précis. It really chimes with my earlier posts as to what's behind the share price rise - i.e. no specific reason but a combination of favourable factors. I've seen JD present - and had lengthy post-presentation conversations a handful of times and he's always refreshing, affable, to the point and cautiously optimistic. I suspect the share price got ahead of itself a little; and suspect we'll see a decline to late 40s / early 50s with no acquisition news. Regardless, it's a great company with solid prospects and one to tuck away. Thanks again.
12/8/2015
21:29
michaelmcandrew: Attended this evening's Shares Magazine presentation by John Dawson. His input was about the company in general with no new financial information. His figures were taken from the 2014 annual results so I won't rehash them - they are all in the annual report. He was obviously constrained about revealing new information by the impending interim results in early September. [So, a strange time to do the presentation?] The Q&A were interesting [but not surprising for those of us who have heard JD speak in the past] :- * APH has facilities of £18m approved and available for purchases * any acquisitions will be established products with no marketing risk * before a product is bought in there is a very extensive due diligence process to try and ensure that there has been no cooking of the books by the vendor * there is no R&D spend because APH doesn't do R&D but they do spend extensively on promotion [within limits that do not damage profitability] * It is capitalism when a company is bought because it has a higher break-up value than it's cost. APH would rely on shareholders perception of future prospects to ward off any approach * JD knows of nothing driving the recent rise in the share price. Suggested that the company had treaded water and faced headwinds over the past 3 or 4 years resulting in nervousness amongst investors. He thought that there was now a perception that the headwinds had abated leading to the rise in share price. There had been a number of very large purchases recently.
06/8/2015
12:36
rivaldo: Hardman have just released their monthly research summary for August. There's a brief summary of APH's trading update - nothing new, but the inbvestment summary is a useful précis: "Investment summary and share performance: The share price has performed very strongly over the past month, rising 36% and underpinned by above-average trading volumes, as the market reflected on the trading statement and future outlook for growth. Trading on FY15 prospective PE of 16.7x with a 2014-2018 EPS CAGR estimate of 10%, EV/EBITDA of 12.1x with a FCF yield of 6.1%. The dividend yield is 1.9% and 3.1x covered. Interim results are due to be released on 9th September."
06/7/2015
07:42
rivaldo: This tip in Money Week hasn't been posted here: Http://moneyweek.com/money-morning-aim-stocks-bargains/ "Alliance Pharma (Aim: APH) is one example of an Aim stock that we think has promise. Its business model is based on picking up established but less well-known drugs that it thinks are undervalued by their companies, with a view to getting the maximum amount of money from them. It has a portfolio covering over 50 treatments, and specialises in cancer and dermatology drugs. In April it bought MacuVision, which has a successful treatment for macular degeneration, an age-related eye problem. Despite the fact that Alliance Pharma’s share price has risen by over 20% since we last tipped it in November, it still trades at only 10.3 times forecast 2016 earnings."
02/7/2015
08:45
rivaldo: I picked some of these up on the dip at just above 38p, so going pretty well to date. I liked the look of the company when I saw them present a while back. Should be a nice solid long-termer, with room for sudden jumps in forecasts and the share price on further company or product acquisitions.
24/4/2015
08:11
mazarin: I find it odd to find ADVFN regularly 'mis-quote' APH share Price by as much as 3% at times. Today for example APH opened up 1.25p at 43p, but ADVFN show it as unchanged at 41.8p, both Google and APH's own webpage show it at 43p.
Alliance Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20160930 22:04:32